Related Experiment Video
Updated: May 24, 2026

The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement
Rita Selby1, Bijan J Borah, Heather P McDonald
1Division of Hematology, University of Toronto, Toronto, Canada.
Insights
Only 40% of hip and knee replacement patients receive recommended blood clot prevention. Not receiving this prophylaxis significantly increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Area of Science:
- Orthopedic Surgery
- Cardiology
- Pharmacology
Background:
- The American College of Chest Physicians (ACCP) provides guidelines for thromboprophylaxis in total hip replacement (THR) and total knee replacement (TKR) patients.
- Real-world adherence to these guidelines and its impact on patient outcomes remain under investigation.
Purpose of the Study:
- To assess adherence to ACCP thromboprophylaxis guidelines in THR/TKR patients.
- To compare venous thromboembolism (VTE) and bleeding event rates between patients receiving guideline-recommended prophylaxis and those who did not.
Main Methods:
- Retrospective observational study utilizing a US health plan claims database linked to inpatient medication and mortality data.
- Analysis of THR/TKR patients who underwent surgery between April 2004 and December 2006.
- Comparison of VTE and bleeding events using chi-squared tests and multivariate logistic regression.
Main Results:
- Only 40% of 3,497 analyzed patients received ACCP-recommended thromboprophylaxis.
- Non-ACCP patients had nearly double the risk of DVT (3.76% vs. 2.01%) and over eight times the risk of PE (1.19% vs. 0.14%) compared to ACCP patients.
- No significant difference in bleeding rates was observed between the groups.
Conclusions:
- Adherence to ACCP thromboprophylaxis guidelines in THR/TKR patients is suboptimal in the US.
- Failure to receive ACCP-recommended thromboprophylaxis is an independent risk factor for developing DVT and PE post-surgery.
Background:
The American College of Chest Physicians (ACCP) guidelines recommends thromboprophylaxis for total hip replacement (THR) and total knee replacement (TKR) patients. We examined alignment with ACCP thromboprophylaxis guidelines among THR/TKR patients, and compared symptomatic venous thromboembolism (VTE), bleeding event rates and risk factors for VTE between patients receiving ACCP-recommended thromboprophylaxis ('ACCP') and those who did not ('non-ACCP').
Methods:
This retrospective observational study used a large US health plan claims database that was linked to an inpatient database containing detailed inpatient medication use and a database containing date-of-death information. Patients who had THR/TKR surgery between April 01, 2004 and December 31, 2006 were included. Comparisons of VTE and bleeding events between ACCP and non-ACCP patients were analyzed using chi-squared tests and multivariate logistic regression.
Results:
Of 3,497 linked patients, 1,395 (40%) received ACCP recommended thromboprophylaxis. Of the patients who received non-ACCP recommended prophylaxis the majority (81%) received shorter than the recommended minimum 10 day prophylaxis and 118 (5.6%) of patients received no prophylaxis. Overall, non-ACCP patients were almost twice as likely to experience an incident DVT (3.76% versus 2.01%, p=0.003) and more than eight times as likely to experience an incident PE (1.19% versus 0.14%, p=0.001) relative to ACCP patients; there were no statistically significant difference in bleeding rates. Multivariate logistic regression indicated that the odds of a VTE event were significantly lower for ACCP patients (DVT: OR=0.54; p=0.006; PE: OR=0.12; p=0.004).
Conclusions:
This study offers a unique perspective on 'real-world' thromboprophylaxis patterns and associated outcomes in THR and TKR patients in the US. It suggests that only 40% of THR/TKR patients receive ACCP-recommended thromboprophylaxis and that not receiving ACCP thromboprophylaxis is an independent risk factor for both DVT and PE.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins